Bretylium tosylate
(Synonyms: 托西溴苄铵) 目录号 : GC30874
A class III antiarrhythmic agent
Cas No.:61-75-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Bretylium is a class III antiarrhythmic agent and an inhibitor of the Na+/K+-ATPase (IC50 = 4.5 mM).1 Bretylium also has antiadrenergic activity, inhibiting auricular nerve stimulation-induced vasoconstriction in isolated rabbit ears and hypogastric nerve stimulation-induced contraction of isolated rabbit uterus.2 It inhibits neuroeffector calcium transients (NCTs), as well as increases action potential delay and the absolute refractory period, but does not inhibit field stimulus-induced CTs in isolated mouse vas deferens sympathetic nerve terminals.3 Bretylium prevents ventricular fibrillation in anesthetized dogs in a model of sudden coronary death when administered at a dose of 10 mg/kg.4 Formulations containing bretylium were previously used in the prevention and treatment of ventricular fibrillation.
1.Helms, J.B., Arnett, K.L., Gatto, C., et al.Bretylium, an organic quaternary amine, inhibits the Na,K-ATPase by binding to the extracellular K-siteBlood Cells Mol. Dis.32(3)394-400(2004) 2.Boura, A.L., Copp, F.C., and Green, A.F.New antiadrenergic compoundsNature184BA70-BA71(1959) 3.Brain, K.L., and Cunnane, T.C.Bretylium abolishes neurotransmitter release without necessarily abolishing the nerve terminal action potential in sympathetic terminalsBr. J. Pharmacol.153(4)831-839(2007) 4.Holland, K., Patterson, E., and Lucchesi, B.R.Prevention of ventricular fibrillation by bretylium in a conscious canine model of sudden coronary deathAm. Heart J.105(5)711-717(1983)
| Cas No. | 61-75-6 | SDF | |
| 别名 | 托西溴苄铵 | ||
| Canonical SMILES | C[N+](C)(CC)CC1=CC=CC=C1Br.O=S(C2=CC=C(C)C=C2)([O-])=O | ||
| 分子式 | C18H24BrNO3S | 分子量 | 414.36 |
| 溶解度 | DMSO : ≥ 30 mg/mL (72.40 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4134 mL | 12.0668 mL | 24.1336 mL |
| 5 mM | 0.4827 mL | 2.4134 mL | 4.8267 mL |
| 10 mM | 0.2413 mL | 1.2067 mL | 2.4134 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet